Clinical Trial Update: Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi [Phase 3]

View source ↗

Summary

Long-term follow-up study in patients treated with onasemnogene abeparvovec-xioi in a Phase 3 trial; the study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinal Muscular Atrophy

Drugs mentioned

• Zolgensma (onasemnogene abeparvovec)

Snippet

Sponsor: Novartis Gene Therapies | Conditions: Spinal Muscular Atrophy Type I, Spinal Muscular Atrophy Type II | Phase 3 | Status: ACTIVE_NOT_RECRUITING